Treatment with retifanlimab plus carboplatin-paclitaxel statistically significantly reduced the risk of progression or death by 37% compared with placebo plus carboplatin-paclitaxel.

The combination of toripalimab, nimotuzumab, and chemotherapy showed “promising antitumor activity with acceptable toxicity,” researchers wrote.

Combining TTFields with gemcitabine and nab-paclitaxel can improve OS in patients with locally advanced pancreatic adenocarcinoma, results of the PANOVA-3 trial suggest.

Immuneering has reported 94% overall survival (OS) at six months in first-line pancreatic cancer, emboldening the biotech to ...

The Global Albumin Market is expected to grow at a rate of 6% by 2026. The development of albumin-based nanoparticles for drug delivery, high demand for albumin in R&D activities & clinical trials, ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

During a Community Case Forum event, Adil Daud, MD, discussed immunotherapy options for cutaneous squamous cell carcinoma.

Retifanlimab-dlwr (Zynyz) was granted approval from the FDA for treatment of locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC), both in combination chemotherapy and as a ...

We conducted an international, randomized, phase 3 trial comparing second-line trastuzumab deruxtecan at a dose of 6.4 mg per kilogram of body weight with ramucirumab plus paclitaxel in patients ...

In this global phase III trial, 571 patients with newly diagnosed LA-PAC were randomly assigned to receive gemcitabine 1,000 mg/m 2 and nab-paclitaxel 125 mg/m 2 by intravenous infusion once a day on ...